The data obtained in our in vitro model (summarized in Figure 8) indicate that the antihypertensive drug TLM acts as an agonist of the PPAR-γ nuclear receptor in cells of OL lineage, promoting OP differentiation under physiological and pathological conditions, such as those mimicking the accumulation of intracellular cholesterol and morphological alterations typical of NPC disease. Here, PPARG is linked to nasopharyngeal carcinoma.